Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

David De La Zerda

Pulmonary Disease Deerfield Beach, FL Medical Doctor

NPI 1245469923 CMS profile 193053

1 W Sample Rd Ste 201, Deerfield Beach, FL 33064

Open in the dashboard

General payments

$15,539

25 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,223,304 paid to institutions, not to them · program years 2019–2022

Through program year 2025, David De La Zerda of Deerfield Beach, FL is reported in the CMS Open Payments database as having received $15,539 across 25 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $1,223,304 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 86th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $96 4
2021 General $2,020 2
2020 General $3,144 7
2019 General $10,279 12

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David De La Zerda
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to David De La Zerda were reported at $96. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year David De La Zerda Pulmonary Disease median Middle half National median
2019 $10,279 $377 $109–$1,340 $163
2020 $3,144 $230 $56–$907 $114
2021 $2,020 $269 $68–$1,072 $132
2022 $0 $390 $100–$1,457 $149
2023 $0 $419 $114–$1,659 $160
2024 $0 $476 $123–$1,818 $164
2025 $96 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Actelion Pharmaceuticals US, Inc. $15,367 17 payments
  2. United Therapeutics Corporation $69 3 payments
  3. Ambu Inc. $40 2 payments
  4. Merck Sharp & Dohme Corporation $38 2 payments
  5. Liquidia Technologies, Inc. $25 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $14,050 9 payments
  2. Travel and Lodging $1,033 4 payments
  3. Food and Beverage $443 11 payments
  4. Education $13 1 payment
Products named General payments · program years 2019–2025
  1. UPTRAVI Cardiovascular Disorders $10,150 10 payments
  2. UPTRAVI Cardiology $5,112 6 payments
  3. OPSUMIT $2,020 2 payments
  4. BOSENTAN $105 1 payment
  5. TYVASO $46 2 payments
  6. YUTREPIA $25 1 payment
  7. WINREVAIR $25 1 payment
  8. ORENITRAM $23 1 payment
  9. ZERBAXA $13 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

502

Median for Critical Care (Intensivists): 406

Drug cost

$5,479,747

Median for Critical Care (Intensivists): $197,260

Branded share of claims

69.9%

Median for Critical Care (Intensivists): 69%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Opsumit Macitentan Brand 135 $1,716,555
Uptravi Selexipag Brand 63 $1,565,186
Adempas Riociguat Brand 68 $850,160
Tyvaso Dpi Treprostinil Brand 36 $836,455
Letairis Ambrisentan Brand 27 $342,931
Ambrisentan Generic 33 $91,507
Revatio Sildenafil Citrate Brand 11 $63,155
Sildenafil Citrate Generic 85 $12,899
Tadalafil Generic 13 $717
Furosemide Generic 20 $133

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,531 Part D prescribers listed as Critical Care (Intensivists); they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 16 billing codes

Paid by Medicare

$28,912

Medicare's payments for the services billed

Medicare patients

128

Average age 71

Services billed

263

67 women, 61 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 66%
Heart failure 63%
Chronic kidney disease 55%
Depression 55%
Ischemic heart disease 54%
Atrial fibrillation 54%
COPD 48%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

25 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record